CLU and invasive breast carcinoma: Based on the results obtained from TIMER2.0, we found that the expression of CLU was significantly reduced in the tumor tissue of a majority of cancers compared to their matched normal controls, such as bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), and colorectal (COAD and READ) and lung (LUSC and LUAD) cancers.